Clinical Trial Update: A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype [Phase 3]

View source ↗

Summary

This is a Phase 3 trial comparing duvelisib to Gemcitabine or Bendamustine in relapsed/refractory nodal T-cell lymphoma with TFH phenotype. The study is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nodal T-cell Lymphoma with Tfh Phenotype

Drugs mentioned

• Bendamustine (Treanda) (bendamustine)
• Duvelisib (duvelisib)
• Gemcitabine (Gemzar) (gemcitabine)

Snippet

Sponsor: SecuraBio | Conditions: Lymphoma | Phase 3 | Status: RECRUITING